Exclusion of HIV-Positive Patients From Sickle Cell Gene Therapy

This perspective article addresses the exclusion of patients living with HIV from gene therapy for sickle cell disease. The piece analyzes the ethical implications that this exclusion brings for the affected group of patients. It also focuses on the scientific considerations associated with this treatment restriction in modern medicine. The text examines the clinical impacts of this exclusion in medical practice. Furthermore, the discussion includes the manufacturing and technological implications of gene therapies in the presence of HIV infection. The objective of this perspective is to comprehensively evaluate the reasons for and effects of excluding people living with HIV from advanced therapeutic approaches.